Accession Number : ADA266282


Title :   Longterm Follow-Up of Patients in CSP No. 298 'Treatment of Patients with Acquired Deficiency Syndrome (AIDS) and AIDS Related Complex


Descriptive Note : Annual rept. 1 Apr 1992-30 Mar 1993


Corporate Author : DEPARTMENT OF VETERANS AFFAIRS WASHINGTON DC


Personal Author(s) : Simberkoff, M J ; Hamilton, J


Full Text : https://apps.dtic.mil/dtic/tr/fulltext/u2/a266282.pdf


Report Date : 01 Apr 1993


Pagination or Media Count : 16


Abstract : This is the second annual report for the extended follow-up of patients originally enrolled in the VA CSP Study No. 298. The original study was a 4-year, double-blind, placebo-controlled study of the efficacy and safety of azidothymidine (AZT: 250 mg q 4 hr, p.o.) for patients with symptomatic HIV infection and CD4 counts between 200 and 500 cells/cubic mm. In that study we compared the benefits and liabilities of initiating AZT early (i.e., at study enrollment) versus initiating it late (i.e., when AIDS occurred or CD4 counts declined to 200 cells/cubic mm. That study ended in January 1991, finding that early AZT therapy delays the progression to AIDS but does not give a concomitant increase in survival time. The present study is a 3-year extended follow-up of the patients who survived the original study. Its goals are to assess early versus late AZT therapy in terms of long-term morbidity, toxicity, and drug resistance. For this study, the dosage of AZT is 500 mg daily, the dosage now recommended by the manufacturer and the FDA.


Descriptors :   *MEDICAL RESEARCH , *HEALTH SURVEYS , *ACQUIRED IMMUNE DEFICIENCY SYNDROME , SURVIVABILITY , NEUROPHYSIOLOGY , RETROVIRUSES , IMMUNITY , BENEFITS , PATIENTS


Subject Categories : Medicine and Medical Research
      Pharmacology


Distribution Statement : APPROVED FOR PUBLIC RELEASE